Vir Biotechnology Inc
Company Profile
Business description
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Contact
1800 Owens Street
Suite 900
San FranciscoCA94158
USAT: +1 415 906-4324
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
408
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,845.60 | 2.50 | 0.03% |
| CAC 40 | 8,086.05 | 20.11 | -0.25% |
| DAX 40 | 23,960.59 | 116.28 | -0.48% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,774.32 | 89.53 | 0.92% |
| HKSE | 25,468.78 | 233.37 | 0.92% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 49,134.63 | 377.65 | -0.76% |
| NZX 50 Index | 13,265.44 | 30.47 | -0.23% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,562.50 | 6.00 | 0.07% |
| SSE Composite Index | 3,870.28 | 45.47 | 1.19% |